BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future revenue amid shifting company focus. Latest Ratings for BNTX Date Firm Action From To Feb 2022 HC Wainwright & Co. Maintains Buy Feb 2022 Morgan Stanley Maintains Equal-Weight Feb 2022 Redburn Partners Upgrades Sell Neutral View More